Veradigm | MDRX - Des Atouts





Des Atouts Changement Date
Alcidion AUD 118.08M 2.46M 2025-12
Ambu A/S DKK 7.61B 25M 2026-03
Amplifon EUR 3.89B 366.88M 2025-12
Cardinal Health USD 56.69B 1.39B 2026-03
Centene USD 81.18B 4.43B 2026-03
Charles River Laboratories USD 7.73B 594.89M 2026-03
Cigna USD 153.27B 4.65B 2026-03
Coloplast 48.8B 429M 2025-12
Computer Programs Systems USD 402.53M 3.12M 2025-12
Convatec Group USD 3.52B 109.3M 2024-12
CVS Health USD 252.97B 564M 2026-03
Diasorin EUR 2.87B 257.21M 2025-06
Elevance Health USD 125.83B 4.33B 2026-03
General Electric Aerospace USD 128.45B 1.72B 2026-03
Gulf Medical Proj AED 1.55B 85.18M 2025-12
Humana USD 55.28B 6.37B 2026-03
IQVIA Holdings USD 29.68B 269M 2026-03
Laboratory Of America USD 19.09B 694.4M 2026-03
Maximus USD 4.24B 30.87M 2026-03
McKesson USD 82.32B 1.87B 2026-03
Med Life RON 3.26B 116.56M 2025-12
Molina Healthcare USD 16.39B 827M 2026-03
Omnicell USD 2B 29.39M 2026-03
Oriola-kd EUR 946.1M 22.7M 2025-12
Owens Minor USD 2.42B 35.78M 2026-03
Quest Diagnostics USD 16.67B 448M 2026-03
Rede D'or Sao Luiz BRL 109.77B 3.22B 2026-03
Siemens Healthineers EUR 44.81B 548M 2026-03
Sonova Holding CHF 5.92B 468.2M 2025-06
Supermax Corporation Bhd MYR 4.17B 125.99M 2025-12
UnitedHealth USD 312.64B 3.06B 2026-03
Veeva Systems USD 9.13B 150.22M 2026-03
Veradigm USD 1.5B 185.94M 2022-12
Xerox USD 9.9B 79M 2026-03